History Repeats Itself in Silicon Valley’s Most Dangerous Game

Billy Evans – the partner of convicted Theranos founder Elizabeth Holmes – is BACK with a new blood-testing venture that’s triggering alarm bells across Silicon Valley. According to explosive New York Times reporting, Evans is pitching investors on Haemanthus, a startup promising laser-powered health optimization through blood, saliva and urine analysis.

“For many of the same reasons we passed twice on Theranos…”

Jim Breyer, Early Facebook Investor

The Theranos Playbook 2.0?

The parallels are UNCANNY:

• Same bold claims: Cancer detection through “revolutionary” laser technology
• Same staged rollout: Starting with pets before human applications
• Same massive ask: $50M+ funding target

Why This Time Might Be Different (Or Worse)

While Theranos’ Edison devices were exposed as fraudulent, Haemanthus is reportedly using actual laser technology. But medical experts warn:

• No peer-reviewed studies validating their claims
• No FDA approvals for human diagnostics
• The shadow of $9B Theranos valuation collapse looms large

Holmes herself remains incarcerated, yet still claims in interviews to be “completely committed” to her healthcare vision. Meanwhile, Evans moves forward with what some are calling “Theranos: The Next Generation.”

Investor Reactions Speak Volumes

Early Facebook backer Jim Breyer’s team was pitched – and IMMEDIATELY passed. His reason? A chilling echo of Theranos concerns. Other investors are reportedly approaching with extreme caution, remembering how quickly “the next big thing” can become “the next big fraud.”

The billion-dollar question: Will Silicon Valley fall for another blood-testing revolution story, or has Theranos permanently changed the game?